Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy
Colin Reily, Zina Moldoveanu, Tiziano Pramparo, Stacy Hall, Zhiqiang Huang, Terri Rice, Lea Novak, Radko Komers, Celia Jenkinson, Jan Novák
Abstract
The mechanisms by which deposited IgA1 immune complexes cause kidney injury during early phases of IgA nephropathy are poorly understood. We used an animal model we recently developed that involves IgA1-IgG immune complex injections and determined pathways related to the induced mesangioproliferative changes. Treatment with sparsentan, a dual inhibitor of endothelin type A and angiotensin II type 1 receptors, ameliorated the induced mesangioproliferative changes and the associated alterations in the expression of inflammatory genes and networks.
Topics & Concepts
AutoantibodyNephropathyImmune systemGlomerulonephritisImmunologyComplement systemImmune complexBiologyKidneyAntibodyEndocrinologyDiabetes mellitusRenal Diseases and GlomerulopathiesComplement system in diseasesPlatelet Disorders and Treatments